Tislelizumab

Definition

A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.

Also known as BGB A317, BGB-A317, BGBA317, Tevimbra, Tirelizumab, TISLELIZUMAB, Tislelizumab-jsgr — per NCIT

Also identified as

• ATC L01FF09 per RXNORM
• NCIT NCIT:C121775 per NCIT
• SCTID 1363351004 per RXNORM
• UNII 0KVO411B3N per RXNORM

Indications

Organ Effects

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.